<!DOCTYPE html>
<html lang="en-US">
<head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width initial-scale=1.0" />
    <title>VASCEPA (icosapent ethyl) - EPA and DHA</title>
    <meta name="description" content="Learn about the effects that EPA and DHA have on patientsâ€™ lipid levels.">
    <meta name="keywords" content="LDL-C, TG, EPA, DHA, statin therapy, desired lipid effect, undesired lipid effect">
    <link rel="stylesheet" type="text/css" href="../includes/style.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="../includes/main.js"></script>
    <script type="text/javascript">
        if(navigator.userAgent.match(/iPad/i)) {
            viewport = document.querySelector("meta[name=viewport]");
            viewport.setAttribute('content', 'width=960');
        }
    </script>
    <script src="//use.typekit.net/kfd3zyz.js"></script>
    <script>try{Typekit.load({ async: true });}catch(e){}</script>    <script>try{Typekit.load();}catch(e){}</script>
    <script>
        (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
        (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
        m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
        })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
        ga('create', 'UA-60954107-1', 'auto');
        ga('send', 'pageview');
        
    </script>
    <script src="http://crypto-js.googlecode.com/svn/tags/3.1.2/build/rollups/sha1.js"></script>
    <script src="http://services.revhealthbackend.com/js/urlPassword.js"></script>
</head>

<body>
    <div id="wrapper">
        <div id="currentpg" data-current="managing"></div>
        <div id="top-child-content"></div>
        <div id="content" class="content-wrap">
            <div id="page-content">
                <div class="breadcrumbs">
                    <ul>
                        <a href="impact-of-ldl-c.html">
                            <li><p>Impact of LDL-C</p></li>
                        </a>
                        <a href="#">
                            <li class="current-page"><p>EPA and DHA</p></li>
                        </a>
                        <a href="moa-of-epa.html">
                            <li><p>MOA of EPA</p></li>
                        </a>
                        <a href="epa-purity.html">
                            <li><p>EPA purity</p></li>
                        </a>
                        <a href="dietary-supplements.html">
                            <li><p>Dietary supplements</p></li>
                        </a>
                    </ul>
                </div>
                <div class="center-col">
                    <div class="page-text">
                        <h1>EPA and DHA have different effects on lipid levels<sup>1,2</sup></h1>
                        <img class="alignleft button-padding" title="EPA/DHA comparison" src="../includes/uploads/EPA-DHA-test-tubes.png" alt="EPA/DHA comparison" width="279" height="272">
                        <p><a class="button inner-mobile-button" href="#lightbox-content">Fenofibrates</a></p>
                        <p class="mobile-clear">EPA and DHA have been shown to lower TG levels...<sup>1-6.</sup>*</p>
                        <p><em>BUT</em></p>
                        <p>DHA has been shown to increase LDL-C in some patients.<sup>1,2,5-7</sup></p>
                        <ul>
                            <li>The effect of DHA increasing LDL-C on cardiovascular morbidity and mortality has not been established.</li>
                            <li>Any increase in LDL-C is counterproductive to the goals of statin therapy<sup>7,8</sup></li>
                        </ul>
                        <p style="clear: both;"><a class="button inner-button" href="#lightbox-content">Fenofibrates</a></p>
                        <div class="clear" style="margin-bottom: 25px;">
                            <span style="font-size: 12px;">*Studies were conducted in subjects with varying baseline TG levels.</span><br>
                            <span style="font-size: 12px;">DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.</span>
                        </div>
                    </div>
                    <div class="load-child-disclaimer"></div>
                    <div class="references">
                        <strong>References: 1.</strong> Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. <em>J Clin Lipidol</em>. 2012;6(1):5-18. <strong>2.</strong> Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. <em>Curr Atheroscler Rep.</em> 2011;13(6):474-483. <strong>3.</strong> VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2015. <strong>4.</strong> Miller M, Stone NJ, Ballantyne C, et al; on behalf of American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; and Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. <em>Circulation</em>. 2011;123(20):2292-2333. <strong>5.</strong> Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. <em>Postgrad Med.</em> 2014;126(7):7-18. <strong>6.</strong> Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. <strong>7.</strong> Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1&ndash;executive summary. <em>J Clin Lipidol.</em> 2014;8(5):473-488. <strong>8.</strong> Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomized trials. <em>Lancet.</em> 2010;376(9753):1670-1681. 
                    </div>
                    <div id="lightbox-content">
                        <div id="lightbox-wrapper">
                            <div class="lightbox-div">
                                <div id="close">
                                    <img src="../includes/theme-images/close.png" alt="close">
                                </div>
                                <div class="lightbox-text">
                                    <h1>Failed outcomes studies of fenofibrates and niacin in statin-treated patients</h1>

                                    <p>Recent cardiovascular outcomes trials (ACCORD Lipid, AIM-HIGH, and HPS2-THRIVE),</p>
                                    <ul style="list-style-position: inside;">
                                        <li>while not designed to test the effect of lowering TG levels in patients with high TG levels after statin therapy,</li>
                                        <li>each failed to demonstrate incremental cardiovascular benefit of adding a second lipid-altering drug (fenofibrate or formulations of niacin),</li>
                                        <li>despite raising HDL-C and reducing TG levels, among statin-treated patients with well controlled LDL-C.</li>
                                    </ul>
                                    <p>VASCEPA is not FDA-approved for the treatment of statin-treated patients with mixed dyslipidemia and high (&ge;200 mg/dL and &lt;500 md/dL) TG levels</p>
                                    <div class="clear">
                                    <ul style="list-style-position: inside;">
                                        <li>due to current uncertainty regarding the benefit, if any, of drug induced changes in lipid/lipoprotein parameters beyond statin-lowered LDL-C on cardiovascular risk among statin-treated patients with residually high TG.</li>
                                        <li>No prospective study has been conducted to test and support what, if any, benefit exists.</li>
                                    </ul>
                                    <p>The effect of VASCEPA on the risk of cardiovascular mortality and morbidity has not been determined.</p>
                                        <p>A cardiovascular outcomes study of VASCEPA designed to evaluate the efficacy of VASCEPA in reducing cardiovascular mortality and morbidity in a high risk patient population on statin therapy is currently underway (REDUCE-IT).</p>
                                        <p>No studies have been conducted to directly compare the effects of VASCEPA and fenofibrates or VASCEPA and formulations of niacin.</p>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="page-sidebar">
                    <div class="load-child-callout"></div>
                    <div class="load-child-disclaimer"></div>
                </div>
            </div>
        </div>
        <div id="child-footer"></div>
    </div>
</body>
</html>
